Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), has announced the successful completion of patient enrollment for two separate Phase III clinical studies: one for TAB014 and another for epinastine, a generic version of Allergan’s Elestat. This milestone underscores Zhaoke’s commitment to advancing ophthalmic therapies.
TAB014: Targeting Neovascular Wet AMD
TAB014 is a recombinant anti-VEGF antibody being developed for the treatment of neovascular wet age-related macular degeneration (wAMD). The Phase III clinical study is randomized, double-blinded, and non-inferiority in design. Its primary objective is to evaluate baseline changes in best corrected visual acuity (BCVA) at week 52 among patients receiving TAB014 compared to those treated with Novartis’s ranibizumab. This comprehensive study involves 488 patients across 60 centers, with Professor Chen Youxin from Beijing Union Medical College Hospital serving as the primary investigator.
Epinastine: Addressing Seasonal Allergic Conjunctivitis
In addition, the efficacy and safety of epinastine will be evaluated in a multi-center, randomized, double-blinded, positive-controlled Phase III study targeting patients with seasonal allergic conjunctivitis. This study has successfully enrolled 266 patients across 14 centers, further highlighting Zhaoke’s robust pipeline in ophthalmology.
